Noncovalent Bruton tyrosine kinase inhibitors like pirtobrutinib may be a more effective first-line therapy for chronic ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

INDIANAPOLIS (WISH) — Indianapolis-based pharmaceutical giant Eli Lilly and Co. has committed up to $40 million to Indiana University to expand access to clinical trials and innovative treatments for ...

Parkinson's disease affects more than 1.1 million people in the U.S. Early treatment of obstructive sleep apnea -- a condition that causes breathing to briefly pause -- may decrease the risk of ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease. The new guideline ...

Eli Lilly’s (LLY) Alzheimer’s disease drug, donanemab, has been approved by India’s drug regulator and is expected to be launched within the next few months. Donanemab is an amyloid-targeting therapy ...

An experimental MeiraGTx gene therapy that has clinical data showing reversal of blindness in children born with a rare, inherited eye disorder is heading to Eli Lilly. According to the terms of the ...

MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY). MeiraGTx will grant Lilly ...

(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the program to Eli Lilly in a deal potentially worth more than $475 million. The ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to overhaul its approach to therapies for rare diseases. In a position paper, the agency highlighted that rare ...